U.S. Markets closed

Centogene N.V. (CNTG)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
9.11+0.06 (+0.66%)
At close: 4:00PM EDT
Sign in to post a message.
  • H
    Harry
    CNTG is a high growth small cap.
  • Y
    Yahoo Finance Insights
    Centogene is down 8.43% to 10.54
  • k
    kelly
    this one has been dancing around $11.2 to $12.8 since Jul 2020. For this earning, it would be better to be good or it would be really dead stock....
  • Y
    Yahoo Finance Insights
    Centogene is up 8.27% to 13.87
  • Y
    Yahoo Finance Insights
    Centogene is down 8.20% to 11.53
  • e
    ecobiz
    Centogene has announced a number of testing deals in particular Frankfurt Airport and the American schools deal. Does anyone have any insight into how much revenue these tests are generating?
  • k
    kelly
    add more shares and take some gambling today. Hope CNTG bring good Q3 result.
  • Y
    Yahoo Finance Insights
    Centogene is up 7.96% to 12.48
  • k
    kat
    It’s for sale on amazon in Germany now
  • B
    Blue
    Already after the test station at the Frankfurt airport it went steeply upwards. Now Munich Airport is next on the list. The message about the sale via Amazon is
    groundbreaking!
    Bullish
  • G
    Green
    I believe the big drop was due to selling by 3 of the 4 largest shareholders in the secondary stock offer in process. They sold 10-20% of their position. The largest shareholder didn’t sell any. This actually should not much of a surprise. The lock ups from last year’s IPO recently expired and this is a much cleaner way to sell some shares to take advantage of their gains.
  • T
    Tommy
    Bought into CNTG early this morning. Seems under the radar and with ER coming up, it could get a nice boost.
  • k
    kelly
    why is this one red today with good Q3
  • G
    Green
    If they can get the Covid-19 test on Amazon U.S., through the roof!
  • k
    kelly
    It seems that this one dropped more than 9% after hours. Any news to share?
  • L
    Laurie
    Nice move off the news for CNTG, but GNMK seems to be far more advanced and bumped up earnings release to next week after guiding higher.
  • P
    Patrice
    CENTOGENE Reports Third-Quarter 2020 Financial Results and Increases Full Year GuidanceDecember 16, 2020 at 6:30 AM ESTCAMBRIDGE, Mass. and ROSTOCK, Germany and BERLIN, Dec. 16, 2020 (GLOBE NEWSWIRE) -- Centogene N.V. (Nasdaq: CNTG) (?CENTOGENE? or the ?Company?), a commercial-stage company focused on rare diseases that transforms real-world clinical and genetic data into actionable information for patients, physicians, and pharmaceutical companies, today provided an update on its corporate progress and reported its financial results for the three and nine months ended September 30, 2020.Revenues increased 212% compared to Q3 2019, driven by the continued expansion of our COVID-19 testing offeringIncreased 2020 full-year revenue guidance to more than #$%$100 millionContinued growth of new pharma partnerships, with 12 new deals signed and a robust recovery anticipated in 2021Expansion of commercial COVID-19 testing, which now includes antigen testingAnnounced leadership transition and appointment of Dr. Andrin Oswald as Chief Executive Officer to support the next stage of the Company?s growthAndrin Oswald, M.D., Chief Executive Officer at CENTOGENE, said, ?I am excited to have joined CENTOGENE at such an important stage in the Company?s evolution. While I have only been with CENTOGENE for a few weeks, it is clear to me that our entire team is focused on achieving a common goal of helping rare disease patients around the world. We believe that our mission has the potential to significantly reduce the burden of rare diseases ? and offers an exciting value creation opportunity for our stakeholders at the same time. Leveraging more than 20 years of professional experience across the life sciences, including my time at Novartis and the Bill and Melinda Gates Foundation, I am looking forward to helping further scale and accelerate CENTOGENE?s growth as a leader in the rare disease space.?Richard Stoffelen, Chief Financial Officer at CENTOGENE, said, ?During the third quarter, we saw a significant increase in our revenues, year-over-year, driven by our ability to leverage our core competency in precise medical diagnoses to pivot quickly and provide solutions to help address the COVID-19 pandemic. As we approach the end of what has been an unprecedented year, I would like to thank the entire CENTOGENE team once more for their flexibility and unwavering commitment.?A Solid Foundation for 2021CENTOGENE has leveraged its core competency of providing precise medical diagnoses, as well as its infrastructure, to help prevent further outbreaks of SARS-CoV-2 (COVID-19) throughout 2020. As part of this initiative, CENTOGENE has become one of the largest COVID-testing companies in Europe and created a pioneering and leading role in providing testing services at airports. The positive financial contribution from COVID-19 testing will enable the Company to make strategic investments to further solidify its leading position in the rare disease space. The number of Pharma partnership discussions have also continued to increase since Q2 2020, positioning CENTOGENE for further progress in 2021.Further information on the Company?s Q3 2020 Earnings, including the management?s discussion and analysis of financial condition and results of operations, can be found by visiting EDGAR on the SEC website at www.sec.gov, as well as the Investor Relations page of the Company?s website at http://investors.centogene.com.About CENTOGENE
    Bullish
  • Y
    Yahoo Finance Insights
    Centogene is up 18.95% to 14.25
  • N
    Nick
    #cntg testing via amazon going to double today as well as #htbx and #immp and #MTP should be very good buy at this price #abus will hit A $30 ove wining #mrna patent